Treatment with buserelin, an agonist of gonadotropin-releasing hormone, suppresses ovarian hyperstimulation syndrome induced in rabbits.
Oshima
K
K
Pharmacology, Lead Optimization, Drug Innovation & Approval Division, Aventis Pharma Ltd, Saitama 350-1165, Japan. kenichi.oshima@aventis.com
Suzuki
K
K
Makita
S
S
Yoshida
Y
Y
D000818:Animals; D001201:Ascites / Q000473:pathology; D002064:Buserelin / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D008596:Menotropins / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D010053:Ovary / Q000473:pathology; D011374:Progesterone / Q000097:blood; D011817:Rabbits; D014599:Uterus / Q000473:pathology
D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D002064:Buserelin